Optiscan Puts Two Medical Imaging Devices Before the FDA

Two flagship devices enter formal FDA review

Optiscan Imaging Ltd (ASX:OIL) has reached the regulatory gate it has been working towards: its InForm digital pathology device and InVue precision-surgery device are now before the US Food and Drug Administration. The company lodged the 510(k) submissions on 1 October and 5 October respectively, shortly after the September quarter ended.

The submissions move both products from internal development and validation into independent regulatory assessment. Clearance is not assured, and the announcement provides no timetable for an FDA decision. If cleared for their proposed indications, the devices would have the regulatory foundation required for commercial distribution in the US.

The filings cap a substantial technical and clinical workload, including external testing, verification and validation, risk management and quality documentation. The milestone builds on the InForm FDA submission, which was reported earlier in October, while InVue’s application followed days later.

Mayo studies extend the evidence base

Optiscan signed two research agreements with Mayo Clinic in Rochester, Minnesota, covering breast cancer and head and neck cancer imaging. Each study can enrol up to 35 US patients and will assess InVue during surgery alongside InForm’s ex vivo pathology imaging, testing the integrated workflow that sits at the centre of Optiscan’s commercial pitch.

Recruitment has commenced in the head and neck program, while the breast study is also open. The work builds on the Mayo breast cancer study, which had previously been launched to generate evidence for the FDA filings. Optiscan says the studies may help with further FDA information requests, workflow refinement and the creation of future clinical reference sites, but they are not themselves evidence of clearance or commercial adoption.

Australian programs supply clinical depth

The company’s Australian studies continued to provide data across several applications. The Royal Melbourne Hospital breast program had completed 40 of 50 planned cases by 30 September, while the St John of God Murdoch head and neck study had completed 13 cases. Australian Clinical Labs had generated 84 datasets across multiple tissue types and pathologies in its live pathology program.

Those figures indicate activity and evidence generation rather than a disclosed clinical-performance result: the announcement does not provide diagnostic accuracy metrics or quantified patient-outcome data. A gastrointestinal study at Universitätsmedizin Mainz was also initiated, with up to 50 patients expected to contribute data for development of a next-generation flexible endomicroscope.

InSpecta launch adds a commercial test

Optiscan also launched its InSpecta veterinary device in the US at the American Veterinary Medical Association convention in July and continued marketing at industry events during and after the quarter. It engaged an outsourced US business-development team and began searching for a US-based chief commercialisation officer as it prepares for potential human-device clearance.

The announcement describes demonstrations, customer engagement and sales-pipeline development, but reports no material customer revenue or sales conversion from InSpecta’s US launch. Manufacturing capacity was strengthened with two additional precision technicians, while recruitment for a chief operating officer began to support production scale-up.

Regulatory progress comes with a finite cash clock

Optiscan used $1.957 million on research and development during the quarter, driving total operating cash outflow to $3.184 million. It ended September with $11.093 million in cash and cash equivalents, including an $8 million short-term deposit. On the company’s reported burn rate, that represents 3.5 quarters of funding, although the estimate can change as FDA review, clinical work, manufacturing and commercial spending develop.

The next phase therefore has two moving parts: converting submissions into FDA decisions while building enough commercial evidence to justify the infrastructure now being assembled. The key tension is whether regulatory and market progress arrives before the current cash buffer requires a fresh funding decision.